Johnson & Johnson (JNJ) Tops Q2 EPS by 10c, Beats on Revenue; Offers FY24 EPS Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mail
Get Alerts JNJ Hot Sheet
Price: $276.32 +3.81%
Financial Fact:
Selling, marketing and administrative expenses: 4.77B
Today's EPS Names:
KTB, CABO, FDUS, More
Financial Fact:
Selling, marketing and administrative expenses: 4.77B
Today's EPS Names:
KTB, CABO, FDUS, More
Join SI Premium – FREE
Johnson & Johnson (NYSE: JNJ) reported Q2 EPS of $2.82, $0.10 better than the analyst estimate of $2.72. Revenue for the quarter came in at $22.45 billion versus the consensus estimate of $22.34 billion.
GUIDANCE:
Johnson & Johnson sees FY2024 EPS of $10.05, versus the consensus of $10.01.
For earnings history and earnings-related data on Johnson & Johnson (JNJ) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ardent Health Partners, Inc. (ARDT) Tops Q3 EPS by 8c; offers guidance
- Coherent (COHR) PT Raised to $450 at Stifel
- Ship Finance (SFL) Tops Q3 EPS by 14c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
